FDA Panel Backs Regulated Peptide Compounding, Opening Door for Enhanced's Personalized Protocols
ENHA sits 28% above its 52-week low of $2.35.
Summary
An FDA advisory committee voted to recommend six peptides—including BPC-157 and TB-500—for the 503A Bulks List, a critical step toward legal, regulated compounding. This directly validates Enhanced's business model, which has exclusively used licensed compounding pharmacies and built a telehealth platform for personalized peptide protocols. The company already has defined stacks (Wolverine, GLOW, KLOW) ready to deploy once the FDA finalizes the rule, which could take months. With a $1.15B market cap and recent $50M PIPE financing, this regulatory tailwind could significantly expand its addressable market. The vote is a recommendation, not final approval, but the FDA historically follows PCAC guidance. Enhanced's early positioning and medical infrastructure give it a first-mover advantage in a market shifting from unregulated gray-market sales to compliant, prescription-based channels.
At the time of this announcement, ENHA was trading at $3.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.35 to $14.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.